Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO technology was featured as a medical breakthrough in an Oct. 13 AARP article. The article introduces 57-year-old Tommy Saul, who was diagnosed with prostate cancer in...
Search results for - profound
Profound Medical gets FDA 510(k) clearance for first TULSA-PRO AI module, Thermal Boost
Profound Medical (NASDAQ:PROF; TSX:PRN) received FDA 510(k) clearance for its Thermal Boost module for use in conjunction with TULSA-PRO. Thermal Boost enables predictable, customized ablation at the prostate capsule...
RJ ups Profound Medical to strong buy
Raymond James upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “strong buy” from “outperform” with a price target of $20.00, after pricing-in the TULSA-PRO system’s 2025 sales inflection. At mid-day on September 18...
Research Capital ups Profound Medical to speculative buy; PT to $17.25
Research Capital upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “speculative buy” from “hold” and raised its price target to $17.25 from $10.90, after the AMA approved three new Category 1 CPT codes for prostate...
AMA unveils new CPT Category 1 codes for Profound Medical’s TULSA-PRO
Profound Medical (NASDAQ:PROF; TSX:PRN) announced that, with sponsorship and support from multiple physician specialty societies, it has received from the American Medical Association (AMA) three new Current Procedural...
Profound to reveal interim 5-year TACT follow-up data during June 6th webinar
Profound Medical (NASDAQ:PROF; TSX:PRN) will unveil interim five-year follow-up data from its TACT (TULSA-PRO ablation clinical trial) pivotal study at a live webinar event it is hosting on June 6 at 6 pm ET. The...
Profound Medical’s TULSA procedure featured at AUA
Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA procedure was featured in four presentations at the American Urological Association (AUA) annual meeting that reinforced its safety, efficacy and durability, further...
KOL urges offering Profound’s TULSA-PRO to prostate cancer patients as part of informed consent
Y. Mark Hong, M.D., a key opinion leader (KOL) and world recognized urologist, suggests that if physicians aren’t offering or at least talking to their prostate cancer patients about Profound Medical’s (NASDAQ:PROF;...
RJ highlights takeaways from KOL presentations on Profound’s TULSA-PRO
In a new report, Raymond James analyst, Rahul Sarugaser, Ph.D., outlined his five main takeaways from presentations from four key opinion leaders – Yale, UCLA, Mayo Clinic and WellSpan Health – about their clinical...
Raymond James, AGP up Profound Medical PTs as AMA to consider CPT approval
Raymond James raised its price target for Profound Medical (NASDAQ:PROF) to $17 from $15 and reiterated a “strong buy” rating after the company said its application for full CPT-1 reimbursement for TULSA-PRO has been...
